Iovance Biotherapeutics anounces public offering of common stock
Iovance announced it to sell $50 million of its common stock in an underwritten public offering. Iovance intends to grant underwriters a 30-day option to purchase up to $7.5 million of common stock at the public offering price. September 19, 2017